(Total Views: 709)
Posted On: 06/27/2022 10:36:13 PM
Post# of 156257
And it’s not just $1.48 or so. If they hit $250mm annual rev sales target over 4 consecutive Q‘s and/or (looks like) US approval of a combo therapy treatment, there is up to another $1 of CVR folks get making the ultimate acquisition price closer to $2.50 or a $410mm mkt cap ballpark. Question is how much of a discount to the ultimate revenue stream that will end up being.
To ohms point - CYDY should demand a higher premium and/or have a competitive bidding process or partnerships once someone bites. And if they get the HIV BLA (and approval) then that should put a decent floor in the negotiations to start from. So plenty of differences here (thanks for mentioning this to both Drano and ohm)
To ohms point - CYDY should demand a higher premium and/or have a competitive bidding process or partnerships once someone bites. And if they get the HIV BLA (and approval) then that should put a decent floor in the negotiations to start from. So plenty of differences here (thanks for mentioning this to both Drano and ohm)
(2)
(0)
